NASDAQ:ARQL - ArQule Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $5.19 -0.10 (-1.89 %) (As of 07/17/2018 04:00 PM ET)Previous Close$5.29Today's Range$5.05 - $5.2852-Week Range$0.94 - $7.21Volume2.37 million shsAverage Volume1.25 million shsMarket Capitalization$533.82 millionP/E Ratio-13.08Dividend YieldN/ABeta1.01 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. It offers Derazantinib (ARQ 087), a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family that is in a registration trial in intrahepatic cholangiocarcinoma with FGFR2 fusions. The company's clinical-stage products include Miransertib (ARQ 092), an inhibitor of the AKT serine/threonine kinase in Phase 1/2 clinical trial in rare Overgrowth Diseases, Phase 1 clinical trial in the rare disease, and in Phase 1b in oncology in combination with the hormonal therapy and anastrozole; ARQ 751, a next-generation inhibitor of AKT that is in Phase I clinical trial for solid tumors harboring the AKT1 or PI3K mutation; ARQ 761, a ß-lapachone analog evaluated as a promoter of NQO1-mediated programmed cancer cell death which is in Phase 1/2 clinical trial in multiple oncology; and ARQ 531, an orally bioavailable, potent and reversible inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase 1 for B-cell malignancies refractory to other therapeutic options. It has collaboration agreement with Roivant Sciences Ltd. to develop derazantinib, a pan-FGFR inhibitor. ArQule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts. Receive ARQL News and Ratings via Email Sign-up to receive the latest news and ratings for ARQL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:ARQL CUSIP04269E10 Webwww.arqule.com Phone781-994-0300 Debt Debt-to-Equity Ratio1.50 Current Ratio5.42 Quick Ratio5.42 Price-To-Earnings Trailing P/E Ratio-13.08 Forward P/E Ratio-27.32 P/E GrowthN/A Sales & Book Value Annual Sales$4.71 million Price / Sales105.23 Cash FlowN/A Price / CashN/A Book Value$0.16 per share Price / Book32.44 Profitability EPS (Most Recent Fiscal Year)($0.39) Net Income$-29,200,000.00 Net MarginsN/A Return on Equity-281.59% Return on Assets-73.14% Miscellaneous Employees32 Outstanding Shares95,500,000Market Cap$533.82 ArQule (NASDAQ:ARQL) Frequently Asked Questions What is ArQule's stock symbol? ArQule trades on the NASDAQ under the ticker symbol "ARQL." How were ArQule's earnings last quarter? ArQule, Inc. (NASDAQ:ARQL) issued its quarterly earnings data on Monday, May, 7th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.01. The biotechnology company earned $4.14 million during the quarter, compared to analyst estimates of $2.27 million. During the same quarter last year, the business earned ($0.11) earnings per share. View ArQule's Earnings History. When is ArQule's next earnings date? ArQule is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for ArQule. What price target have analysts set for ARQL? 5 Wall Street analysts have issued 1 year target prices for ArQule's stock. Their predictions range from $6.00 to $7.50. On average, they anticipate ArQule's share price to reach $6.8750 in the next year. This suggests a possible upside of 32.7% from the stock's current price. View Analyst Ratings for ArQule. What is the consensus analysts' recommendation for ArQule? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ArQule in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting ArQule? ArQule saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 7,232,229 shares, an increase of 488.8% from the June 15th total of 1,228,267 shares. Based on an average daily volume of 2,889,169 shares, the days-to-cover ratio is currently 2.5 days. Currently, 9.0% of the company's stock are short sold. View ArQule's Current Options Chain. Who are some of ArQule's key competitors? Some companies that are related to ArQule include Global Blood Therapeutics (GBT), Puma Biotechnology (PBYI), Myokardia (MYOK), Prestige Brands (PBH), Phibro Animal Health (PAHC), Insmed (INSM), Cambrex (CBM), Mallinckrodt (MNK), Aimmune Therapeutics (AIMT), PTC Therapeutics (PTCT), AnaptysBio (ANAB), Corcept Therapeutics (CORT), IMMURON Ltd/S (IMRN), Biohaven Pharmaceutical (BHVN) and ARMO Biosciences (ARMO). Who are ArQule's key executives? ArQule's management team includes the folowing people: Mr. Paolo Pucci, CEO & Director (Age 57)Mr. Peter S. Lawrence J.D., Pres, COO & Sec. (Age 55)Mr. Robert J. Weiskopf, CFO & Treasurer (Age 67)Dr. Brian Schwartz, Chief Medical Officer (Age 56)Dawn Schottlandt, Sr. Director of Investor Relations & Corp. Communications Has ArQule been receiving favorable news coverage? Headlines about ARQL stock have trended somewhat positive on Tuesday, Accern reports. The research firm identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. ArQule earned a news sentiment score of 0.07 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 44.33 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. Who are ArQule's major shareholders? ArQule's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BIOTECHNOLOGY VALUE FUND L P (12.30%), Handelsbanken Fonder AB (0.73%) and Essex Investment Management Co. LLC (0.14%). Company insiders that own ArQule stock include Paolo Pucci, Patrick J Zenner, Ran Nussbaum, Ronald M Lindsay and Value Fund L P Biotechnology. View Institutional Ownership Trends for ArQule. Which major investors are buying ArQule stock? ARQL stock was bought by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB and Essex Investment Management Co. LLC. Company insiders that have bought ArQule stock in the last two years include Paolo Pucci, Patrick J Zenner, Ran Nussbaum and Ronald M Lindsay. View Insider Buying and Selling for ArQule. How do I buy shares of ArQule? Shares of ARQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is ArQule's stock price today? One share of ARQL stock can currently be purchased for approximately $5.18. How big of a company is ArQule? ArQule has a market capitalization of $533.82 million and generates $4.71 million in revenue each year. The biotechnology company earns $-29,200,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. ArQule employs 32 workers across the globe. How can I contact ArQule? ArQule's mailing address is ONE WALL STREET, BURLINGTON MA, 01803. The biotechnology company can be reached via phone at 781-994-0300 or via email at [email protected] MarketBeat Community Rating for ArQule (NASDAQ ARQL)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 185 (Vote Outperform)Underperform Votes: 175 (Vote Underperform)Total Votes: 360MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe ARQL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARQL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/17/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?